# Correction: Value of combining biological age with assessment of individual frailty to optimize management of cancer treated with targeted therapies: model of chronic myeloid leukemia treated with tyrosine kinase inhibitors (BIO-TIMER trial)

**Authors:** Mélanie Casile, Gilles Albrand, Clément Lahaye, Benjamin Lebecque, Joévin Besombes, Céline Bourgne, Bruno Pereira, Sandrine Saugues, Caroline Jamot, Eric Hermet, Marc G. Berger

PMC · DOI: 10.1186/s12885-024-12592-0 · BMC Cancer · 2024-07-05

## Full-text entities

- **Diseases:** cancer (MESH:D009369), chronic myeloid leukemia (MESH:D015464)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11225154/full.md

## References

1 references — full list in the complete paper: https://tomesphere.com/paper/PMC11225154/full.md

---
Source: https://tomesphere.com/paper/PMC11225154